Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2/3 Multicenter, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of RGX-121 in Pediatric Subjects With MPS II (Hunter Syndrome)

NCT03566043 is registered in ClinicalTrials.gov with REGENXBIO Inc. as lead sponsor.

NCT NCT03566043
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03566043 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2/3 Multicenter, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of RGX-121 in Pediatric Subjects With MPS II (Hunter Syndrome)
Lead sponsor
REGENXBIO Inc.
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
September 27, 2018
Completion date
August 31, 2025
Enrollment
48 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

mucopolysaccharidosis type ii (mps ii)